Literature DB >> 9816309

TIMP1 and adverse prognosis in non-small cell lung cancer.

K M Fong1, Y Kida, P V Zimmerman, P J Smith.   

Abstract

The tumor inhibitor of metalloproteinase (TIMP) family is a natural inhibitor of several matrix metalloproteinase enzymes which are involved in the process of tumor cell invasion through the extracellular matrix. The aim of this study was to examine TIMP1 RNA expression levels in relation to the clinicopathological features in resected primary non-small cell lung cancer (NSCLC). Total cellular RNA, obtained from 45 cases of NSCLC and adjacent normal lung tissue, was examined using Northern blot analysis. TIMP1 RNA expression levels were heterogeneous in NSCLC but was significantly higher in the adenocarcinoma compared to the squamous cell carcinoma subtype. Although the TIMP1 RNA levels did not correlate with sex, smoking, tumor, node, or TNM stage, there was a statistically significant survival disadvantage for cases with relatively high TIMP1 RNA expression, suggesting a role for TIMP1 in determining the prognosis of resected NSCLC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816309

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein.

Authors:  Ki-Kyung Jung; Xu-Wen Liu; Rosemarie Chirco; Rafael Fridman; Hyeong-Reh Choi Kim
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

3.  Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Authors:  Irene Vejgaard Sorensen; Claus Fenger; Henrik Winther; Niels T Foged; Ulrik Lademann; Nils Brünner; Pernille A Usher
Journal:  J Histochem Cytochem       Date:  2006-03-03       Impact factor: 2.479

4.  Proteases as prognostic markers in cancer.

Authors:  H W Verspaget
Journal:  BMJ       Date:  1998-03-14

5.  Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma.

Authors:  Zhen-Dong Gu; Ke-Neng Chen; Ming Li; Jin Gu; Ji-You Li
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

6.  Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer.

Authors:  Takaki Yoshikawa; Akira Tsuburaya; Osamu Kobayashi; Motonori Sairenji; Yohei Miyagi
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

7.  The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells.

Authors:  Ase Bratland; Erlend Ragnhildstveit; Kristin Bjørnland; Kristin Andersen; Gunhild Mari Maelandsmo; Oystein Fodstad; Fahri Saatcioglu; Anne Hansen Ree
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.

Authors:  Karina Dahl Steffensen; Marianne Waldstrøm; Rikke Kølby Christensen; Annette Bartels; Nils Brünner; Anders Jakobsen
Journal:  BMC Cancer       Date:  2010-05-07       Impact factor: 4.430

9.  DNA Methylation Profiles of Protease Nexin 1 (SERPINE2) Gene in Human Cell Lines.

Authors:  Shan Gao; Peter A Andreasen
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

10.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.

Authors:  L Guedez; W G Stetler-Stevenson; L Wolff; J Wang; P Fukushima; A Mansoor; M Stetler-Stevenson
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.